The 36-month beta value for SAGE is at 0.82. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 3 rating it as “overweight,” 15 as “hold,” and 0 as “sell.”
The public float for SAGE is 54.09M, and currently, shorts hold a 8.16% of that float. The average trading volume for SAGE on February 28, 2025 was 1.91M shares.
SAGE) stock’s latest price update
Sage Therapeutics Inc (NASDAQ: SAGE)’s stock price has plunge by -0.14relation to previous closing price of 7.19. Nevertheless, the company has seen a -1.78% plunge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-14 that NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. (“Sage” or “the Company”) (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SAGE.
SAGE’s Market Performance
Sage Therapeutics Inc (SAGE) has seen a -1.78% fall in stock performance for the week, with a -2.05% decline in the past month and a 35.98% surge in the past quarter. The volatility ratio for the week is 5.02%, and the volatility levels for the past 30 days are at 3.05% for SAGE. The simple moving average for the past 20 days is -0.64% for SAGE’s stock, with a -11.53% simple moving average for the past 200 days.
Analysts’ Opinion of SAGE
Many brokerage firms have already submitted their reports for SAGE stocks, with RBC Capital Mkts repeating the rating for SAGE by listing it as a “Sector Perform.” The predicted price for SAGE in the upcoming period, according to RBC Capital Mkts is $4 based on the research report published on November 21, 2024 of the previous year 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to SAGE, setting the target price at $4 in the report published on October 04th of the previous year.
SAGE Trading at 7.76% from the 50-Day Moving Average
After a stumble in the market that brought SAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.78% of loss for the given period.
Volatility was left at 3.05%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares sank -3.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.57% upper at present.
During the last 5 trading sessions, SAGE fell by -3.08%, which changed the moving average for the period of 200-days by -40.46% in comparison to the 20-day moving average, which settled at $7.22. In addition, Sage Therapeutics Inc saw 32.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SAGE starting from JONAS JEFFREY M, who proposed sale 7,500 shares at the price of $5.53 back on Dec 10 ’24. After this action, JONAS JEFFREY M now owns shares of Sage Therapeutics Inc, valued at $41,441 using the latest closing price.
Stock Fundamentals for SAGE
Current profitability levels for the company are sitting at:
- -10.47 for the present operating margin
- 0.77 for the gross margin
The net margin for Sage Therapeutics Inc stands at -9.71. The total capital return value is set at -0.91. Equity return is now at value -63.37, with -56.06 for asset returns.
Based on Sage Therapeutics Inc (SAGE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -22.57.
Currently, EBITDA for the company is -409.49 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 9.09. The receivables turnover for the company is 4.52for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.42.
Conclusion
In conclusion, Sage Therapeutics Inc (SAGE) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
